Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Benjamin Farkas

Physician Assistant Baltimore, MD Physician Assistant

NPI 1346343647 CMS profile 10811795

900 Caton Ave, Baltimore, MD 21229

Open in the dashboard

General payments

$6,977

463 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Farkas of Baltimore, MD is reported in the CMS Open Payments database as having received $6,977 across 463 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,639 93
2024 General $1,180 72
2023 General $1,211 91
2022 General $2,053 130
2021 General $893 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Farkas
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Benjamin Farkas were reported at $1,639. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Benjamin Farkas Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $893 $132 $37–$438 $132
2022 $2,053 $155 $48–$522 $149
2023 $1,211 $167 $52–$557 $160
2024 $1,180 $178 $55–$600 $164
2025 $1,639 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,237 84 payments
  2. Novartis Pharmaceuticals Corporation $1,078 87 payments
  3. AbbVie, Inc. $946 114 payments
  4. Regeneron Healthcare Solutions, Inc. $586 28 payments
  5. Journey Medical Corporation $498 11 payments
  6. UCB, Inc. $440 19 payments
  7. Sun Pharmaceutical Industries Inc. $292 16 payments
  8. Galderma Laboratories, L.P. $286 17 payments
  9. Pfizer Inc. $239 12 payments
  10. Incyte Corporation $221 15 payments
  11. Other $1,154 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,127 450 payments
  2. Education $850 13 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,090 70 payments
  2. COSENTYX Immunology $540 50 payments
  3. SKYRIZI $459 61 payments
  4. COSENTYX Dermatology $437 31 payments
  5. RINVOQ $400 42 payments
  6. Bimzelx $388 16 payments
  7. DUPIXENT $377 15 payments
  8. SIMPONI ARIA $244 28 payments
  9. STELARA $244 28 payments
  10. SIMPONI $244 28 payments
  11. Other $3,458 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

754

Median for Physician Assistant: 241

Drug cost

$24,313

Median for Physician Assistant: $4,110

Branded share of claims

2.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 111 $5,676
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 11 $5,288
Fluorouracil Generic 56 $3,456
Triamcinolone Acetonide Generic 151 $1,668
Clindamycin Phosphate Generic 44 $1,664
Doxycycline Hyclate Generic 68 $1,294
Gentamicin Sulfate Generic 29 $1,172
Ketoconazole Generic 96 $1,143
Betamethasone Dipropionate Generic 35 $981
Metronidazole Generic 11 $546

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$170,571

Of which drugs: $31

Medicare patients

1,051

Average age 74

Services billed

4,058

451 women, 600 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 44%
Ischemic heart disease 27%
Diabetes 18%
Cancer 18%
Atrial fibrillation 15%
Chronic kidney disease 15%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Methotrexate sodium, 50 mg J9260 Office 11 17 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $230
$230 — —
Bimzelx
  • UCB, Inc. $212
$212 — —
RINVOQ
  • AbbVie, Inc. $154
$154 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $98
  • GENZYME CORPORATION $29
$127 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record